PDC Therapeutics
- Biotech or pharma, therapeutic R&D
PDC Therapeutics advances Sagitta®, a clinically-validated, biodegradable polymer-drug conjugate platform delivering targeted oncology therapies with unprecedented payload capacity (DAR >30), ensuring very high tumor accumulation. Sagitta® is versatile - also optimized for radioligand delivery, significantly broadening therapeutic applications. Our lead clinical candidate shows promising efficacy results, validating the platform’s transformative potential. Actively seeking pharmaceutical and biotech partners for co-development, licensing, and strategic alliances. Additionally, our parent company, RS Research, is launching its pivotal Series B investment round - to scale this impactful oncology pipeline globally, positioned precisely at an inflection point towards clinical-scale commercialization and M&A readiness.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}